Zimmer (ZBH) Reports Q2 Earnings: What Key Metrics Have to Say

For the quarter ended June 2025, Zimmer Biomet (ZBH) reported revenue of $2.08 billion, up 7% over the same period last year. EPS came in at $2.07, compared to $2.01 in the year-ago quarter.The reported revenue compares to the Zacks Consensus Estimate of $2.04 billion, representing a surprise of +1.59%. The company delivered an EPS surprise of +4.55%, with the consensus EPS estimate being $1.98.While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.Here is how Zimmer performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:Net Sales- Knees- United States: $448.7 million compared to the $451.86 million average estimate based on four analysts. The reported number represents a change of +1.7% year over year.Net Sales- Hips- United States: $272.5 million compared to the $267.81 million average estimate based on four analysts. The reported number represents a change of +5.2% year over year.Net Sales- Hips- International: $263.6 million versus $256.18 million estimated by four analysts on average. Compared to the year-ago quarter, this number represents a +6.5% change.Net Sales- Knees- International: $377.3 million versus $376.44 million estimated by four analysts on average. Compared to the year-ago quarter, this number represents a +4.8% change.Net Sales- International: $903.5 million versus $872.89 million estimated by three analysts on average. Compared to the year-ago quarter, this number represents a +8.1% change.Net Sales- United States: $1.17 billion versus the three-analyst average estimate of $1.17 billion. The reported number represents a year-over-year change of +6.1%.Net Sales- Knees: $826 million versus $823.52 million estimated by eight analysts on average. Compared to the year-ago quarter, this number represents a +3.1% change.Net Sales- Technology & Data, Bone Cement and Surgical: $164.6 million compared to the $164.64 million average estimate based on eight analysts.Net Sales- S.E.T: $550.6 million versus the eight-analyst average estimate of $536.91 million. The reported number represents a year-over-year change of +17.3%.Net Sales- Hips: $536.1 million versus $522.85 million estimated by eight analysts on average. Compared to the year-ago quarter, this number represents a +5.8% change.View all Key Company Metrics for Zimmer here>>>Shares of Zimmer have returned -4.3% over the past month versus the Zacks S&P 500 composite's +1.2% change. The stock currently has a Zacks Rank #4 (Sell), indicating that it could underperform the broader market in the near term.Beyond Nvidia: AI's Second Wave Is HereThe AI revolution has already minted millionaires. But the stocks everyone knows about aren't likely to keep delivering the biggest profits. Little-known AI firms tackling the world's biggest problems may be more lucrative in the coming months and years.See "2nd Wave" AI stocks now >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Zimmer Biomet Holdings, Inc. (ZBH): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).Zacks Investment ResearchWeiter zum vollständigen Artikel bei Zacks Weiter zum vollständigen Artikel bei Zacks